Real-world treatment patterns and outcomes in patients with CLL and cardiovascular comorbidities: Interim analysis of the multicenter study conducted by eric.
Thomas Chatzikonstantinou(G. Papanikolaou General Hospital), Lydia Scarfò(IRCCS Ospedale San Raffaele), Persefoni Talimtzi(Centre for Research and Technology Hellas), Livio Trentin(University of Padua), Davide Rossi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Ιoannis Kotsianidis(Democritus University of Thrace), Yair Herishanu(Tel Aviv University), Εliana Konstantinou(National and Kapodistrian University of Athens), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Alexandros Machairas(Laiko General Hospital of Athens), Antonio Cuneo(University of Ferrara), Alessandro Gozzetti(University of Siena), Ritu Gupta(Chandigarh University), George Vrachiolias(Democritus University of Thrace), Leila Perobelli(Dr. Euryclides Hospital de Jesus Zerbini), Celso Arrais‐Rodrigues(Hotel Dieu Hospital), Anastasia Chatzidimitriou(Karolinska Institutet), Marta Coscia(University of Turin), Gian Matteo Rigolin, Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Andrea Visentin(University of Padua), Κώστας Σταματόπουλος(Centre for Research and Technology Hellas), Eleftheria Hatzimichael(Thomas Jefferson University), Francesc Bosch Albareda(Universitat Autònoma de Barcelona), Roberta Murru, Carlos Chiattone(Faculdade de Ciências Médicas da Santa Casa de São Paulo), Panagiotis Panagiotidis(National and Kapodistrian University of Athens), Theodoros P. Vassilakopoulos(National and Kapodistrian University of Athens), Lata Rani(Chitkara University), Maria Dimou(National and Kapodistrian University of Athens), Eva Minga(Centre for Research and Technology Hellas), Maria K. Angelopoulou(Laiko General Hospital of Athens), Francesco Angotzi(University of Padua), Ángel Serna(Vall d'Hebron Institut de Recerca), Samir Mouhssine(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Paolo Ghia(Vita-Salute San Raffaele University), Ilaria Romano(University of Padua), Andreas Epameinondas Koumpis(University of Ioannina), Maria Papaioannou(AHEPA University Hospital), Francesca Martini(University of Pisa), Marta Campreciós Crespo(Universitat Autònoma de Barcelona), Caterina Chessa, Niki Stavrogianni(G. Papanikolaou General Hospital), Marcello Bradaschia(University of Siena), Candida Vitale(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino)
Cited by 0
Related Papers
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
An extensive review on the consequences of chemical pesticides on human health and environment
|Journal of Cleaner Production|2020|1.3k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890